PYC Therapeutics Ltd (PYC) - Total Liabilities
Based on the latest financial reports, PYC Therapeutics Ltd (PYC) has total liabilities worth AU$13.27 Million AUD (≈ $9.39 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore PYC Therapeutics Ltd (PYC) investment intensity to see how much of total assets are deployed in long-term investments.
PYC Therapeutics Ltd - Total Liabilities Trend (2004–2025)
This chart illustrates how PYC Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see PYC Therapeutics Ltd total assets.
PYC Therapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of PYC Therapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cementos Pacasmayo SAA ADR
NYSE:CPAC
|
USA | $1.85 Billion |
|
Lenzing Aktiengesellschaft
VI:LNZ
|
Austria | €3.29 Billion |
|
Jiangxi Guoguang Commercial Chains Co Ltd
SHG:605188
|
China | CN¥1.61 Billion |
|
Southern Cross Electrical Engineering Ltd
AU:SXE
|
Australia | AU$281.07 Million |
|
CNB Financial Corporation
NASDAQ:CCNE
|
USA | $7.52 Billion |
|
Morguard Corporation
TO:MRC
|
Canada | CA$7.15 Billion |
|
Guangzhou Automobile Group Co. Ltd
F:02G
|
Germany | €115.67 Billion |
|
Jiangxi Xinyu Guoke Technology Co Ltd Class A
SHE:300722
|
China | CN¥223.36 Million |
Liability Composition Analysis (2004–2025)
This chart breaks down PYC Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See PYC Therapeutics Ltd (PYC) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 12.43 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PYC Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PYC Therapeutics Ltd (2004–2025)
The table below shows the annual total liabilities of PYC Therapeutics Ltd from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$13.27 Million ≈ $9.39 Million |
+30.31% |
| 2024-06-30 | AU$10.18 Million ≈ $7.21 Million |
+16.75% |
| 2023-06-30 | AU$8.72 Million ≈ $6.17 Million |
+69.40% |
| 2022-06-30 | AU$5.15 Million ≈ $3.64 Million |
+28.20% |
| 2021-06-30 | AU$4.02 Million ≈ $2.84 Million |
+197.35% |
| 2020-06-30 | AU$1.35 Million ≈ $955.77K |
+236.12% |
| 2019-06-30 | AU$401.87K ≈ $284.35K |
-77.32% |
| 2018-06-30 | AU$1.77 Million ≈ $1.25 Million |
+18.97% |
| 2017-06-30 | AU$1.49 Million ≈ $1.05 Million |
+3.74% |
| 2016-06-30 | AU$1.44 Million ≈ $1.02 Million |
+74.26% |
| 2015-06-30 | AU$823.80K ≈ $582.89K |
+2.28% |
| 2014-06-30 | AU$805.48K ≈ $569.93K |
-24.55% |
| 2013-06-30 | AU$1.07 Million ≈ $755.39K |
+33.25% |
| 2012-06-30 | AU$801.17K ≈ $566.88K |
-38.77% |
| 2011-06-30 | AU$1.31 Million ≈ $925.74K |
-34.81% |
| 2010-06-30 | AU$2.01 Million ≈ $1.42 Million |
+27.36% |
| 2009-06-30 | AU$1.58 Million ≈ $1.12 Million |
+91.17% |
| 2008-06-30 | AU$824.36K ≈ $583.29K |
-38.36% |
| 2007-06-30 | AU$1.34 Million ≈ $946.24K |
+86.28% |
| 2006-06-30 | AU$717.91K ≈ $507.97K |
+136.46% |
| 2005-06-30 | AU$303.61K ≈ $214.83K |
-51.65% |
| 2004-06-30 | AU$628.00K ≈ $444.35K |
-- |
About PYC Therapeutics Ltd
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program, which is in Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for treating blinding eye disease named Autosomal Dominant Optic Atroph… Read more